Seattle Genetics (SGEN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics Reports Third Quarter 2016 Financial Results
October 27, 2016 4:02 PM EDT-Third Quarter 2016 Revenues Were $106.3 Million, Including Record $70.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-Broad Presence at Upcoming American Society of Hematology (ASH) Annual Meeting, Including an Oral Presentation on the ALCANZA Phase 3 Trial and Four Oral Presentations on Vadastuximab Talirine (SGN-CD33A)-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)--... More
